Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIDGES: Resection and GammaTile vs Standard of Care in Newly Diagnosed Glioblastoma
NCT07195591Phase 3Recruiting
- Sponsor
- GT Medical Technologies
- Start
- Dec 2025
- Primary completion
- Dec 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) (2 arms), sponsored by GT Medical Technologies. Primary endpoint: Overall Survival. Started Dec 2025; status: recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07195591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195591.